Carregant...
Immunotherapy for head and neck cancer: Recent advances and future directions
Three randomized phase III trials have now conclusively proven that exposure to a PD-1 inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such agents should be used in the management of all patients who do not have contraindications to their use. Two of these phase...
Guardat en:
| Publicat a: | Oral Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7749717/ https://ncbi.nlm.nih.gov/pubmed/31683169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.104460 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|